Vanda Pharmaceuticals Inc. (VNDA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '16: 38.5M Q4 '16: 38.2M Q1 '17: 37.4M Q2 '17: 42.1M Q3 '17: 41.3M Q4 '17: 44.3M Q1 '18: 43.6M Q2 '18: 47.4M Q3 '18: 49.1M Q4 '18: 53M Q1 '19: 47.7M Q2 '19: 59.1M Q3 '19: 59.5M Q4 '19: 60.9M Q1 '20: 58M Q2 '20: 62.2M Q3 '20: 60.3M Q4 '20: 67.7M Q1 '21: 62.7M Q2 '21: 67.9M Q3 '21: 70.1M Q4 '21: 68M Q1 '22: 60.2M Q2 '22: 64.4M Q3 '22: 65.3M Q4 '22: 64.5M Q1 '23: 62.5M Q2 '23: 46.1M Q3 '23: 38.8M Q4 '23: 45.3M Q1 '24: 47.5M Q2 '24: 50.5M Q3 '24: 47.7M Q4 '24: 53.2M Q1 '25: 50M Q2 '25: 52.6M Q3 '25: 56.3M Q4 '25: 57.2M Q1 '26: 51.7M Q2 '26: 50.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 25M 50M 75M Q1 '14: 9.1M Q2 '14: 10.7M Q3 '14: 14.1M Q4 '14: 14.7M Q1 '15: 13M Q2 '15: 18.9M Q3 '15: 18.9M Q4 '15: 22.7M Q1 '16: 24.4M Q2 '16: 26.6M Q3 '16: 28.5M Q4 '16: 30.9M Q1 '17: 33M Q2 '17: 37.1M Q3 '17: 36.4M Q4 '17: 39.1M Q1 '18: 38.7M Q2 '18: 41.7M Q3 '18: 43.7M Q4 '18: 47M Q1 '19: 42.2M Q2 '19: 52.3M Q3 '19: 52.3M Q4 '19: 54.3M Q1 '20: 52.4M Q2 '20: 56M Q3 '20: 54M Q4 '20: 60.9M Q4 '14 Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -653K Q4 '16: -654K Q1 '17: -7.9M Q2 '17: -1.9M Q3 '17: -4.9M Q4 '17: -2.1M Q1 '18: 2.4M Q2 '18: 3.9M Q3 '18: 6.2M Q4 '18: 9.2M Q1 '19: -2.1M Q2 '19: 9.9M Q3 '19: 10.8M Q4 '19: 4.2M Q1 '20: -125K Q2 '20: 9.2M Q3 '20: 7.7M Q4 '20: 10.5M Q1 '21: 10.3M Q2 '21: 12.4M Q3 '21: 10.8M Q4 '21: 8.6M Q1 '22: -7.7M Q2 '22: 3.5M Q3 '22: 3.9M Q4 '22: 6.6M Q1 '23: 2M Q2 '23: -2.9M Q3 '23: -6M Q4 '23: -7.1M Q1 '24: -9.2M Q2 '24: -10.1M Q3 '24: -11M Q4 '24: -10.3M Q1 '25: -41M Q2 '25: -38.5M Q3 '25: -31.3M Q4 '25: -40.4M Q1 '26: -50.2M Q2 '26: -63.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q2 '16: -4.6M Q3 '16: -430K Q4 '16: -604K Q1 '17: -7.6M Q2 '17: -1.5M Q3 '17: -4.5M Q4 '17: -1.8M Q1 '18: 3.1M Q2 '18: 4.6M Q3 '18: 7.2M Q4 '18: 10.4M Q1 '19: -612K Q2 '19: 11.5M Q3 '19: 100.4M Q4 '19: 4.2M Q1 '20: 486K Q2 '20: 8.7M Q3 '20: 5.9M Q4 '20: 8.2M Q1 '21: 8.7M Q2 '21: 9.7M Q3 '21: 7.8M Q4 '21: 7.1M Q1 '22: -6.4M Q2 '22: 2.6M Q3 '22: 3.3M Q4 '22: 6.9M Q1 '23: 3.3M Q2 '23: 1.5M Q3 '23: 137K Q1 '24: -4.1M Q2 '24: -4.5M Q3 '24: -5.3M Q4 '24: -4.9M Q1 '25: -29.5M Q2 '25: -27.2M Q3 '25: -22.6M Q4 '25: -141.2M Q1 '26: -48.6M Q2 '26: -62.5M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '19: 5.1M Q2 '19: 6.4M Q3 '19: 6.8M Q4 '19: 6.2M Q1 '20: 5.2M Q2 '20: 5.8M Q3 '20: 5.9M Q4 '20: 6.4M Q1 '21: 6M Q2 '21: 6.6M Q3 '21: 6.8M Q4 '21: 6.2M Q1 '22: 5.7M Q2 '22: 6.1M Q3 '22: 6.3M Q4 '22: 6.2M Q1 '23: 4.8M Q2 '23: 3.5M Q3 '23: 3.1M Q4 '23: 3.5M Q1 '24: 3.4M Q2 '24: 2.7M Q3 '24: 2.6M Q4 '24: 2.6M Q1 '25: 3.5M Q2 '25: 2.7M Q3 '25: 3M Q4 '25: 3.8M Q1 '26: 3.2M Q2 '26: 3.6M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: 1.2M Q4 '16: -1.2M Q1 '17: -5.4M Q2 '17: -2.3M Q3 '17: 2.2M Q4 '17: 3.5M Q1 '18: 1.6M Q2 '18: 4.4M Q3 '18: 8.7M Q4 '18: 15.3M Q1 '19: 9.6M Q2 '19: 20.5M Q3 '19: 6M Q4 '19: 9.8M Q1 '20: -907K Q2 '20: 24M Q3 '20: 9.4M Q4 '20: 19.3M Q1 '21: 9.2M Q2 '21: 19M Q3 '21: 9.4M Q4 '21: 26.6M Q1 '22: 4M Q2 '22: 5.7M Q3 '22: 12.8M Q4 '22: 9.4M Q1 '23: 31.8M Q2 '23: -13.2M Q3 '23: -2M Q4 '23: -3.7M Q1 '24: 7.6M Q2 '24: -6.9M Q3 '24: -14.6M Q4 '24: -1.8M Q1 '25: -33.1M Q2 '25: -15.3M Q3 '25: -31.6M Q4 '25: -29.4M Q1 '26: -50.2M Q2 '26: -31.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '16: 642K Q4 '16: -1.9M Q1 '17: -5.8M Q2 '17: -2.9M Q3 '17: 1.8M Q4 '17: 3.3M Q1 '18: 1.5M Q2 '18: 4.3M Q3 '18: 8.6M Q4 '18: 15.2M Q1 '19: 9.2M Q2 '19: 20.3M Q3 '19: 5.7M Q4 '19: 9.7M Q1 '20: -1.3M Q2 '20: 23.8M Q3 '20: 9.1M Q4 '20: 18.3M Q1 '21: 9.1M Q2 '21: 18.7M Q3 '21: 9.4M Q4 '21: 26.5M Q1 '22: 4M Q2 '22: 5.5M Q3 '22: 12.7M Q4 '22: 9.2M Q1 '23: 31.8M Q2 '23: -13.3M Q3 '23: -2.1M Q4 '23: -4M Q1 '24: 7.6M Q2 '24: -7M Q3 '24: -14.7M Q4 '24: -2M Q1 '25: -33.6M Q2 '25: -15.6M Q3 '25: -31.8M Q4 '25: -29.5M Q1 '26: -50.4M Q2 '26: -31.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '10: 28.4M Q3 '10: 28.5M Q1 '11: 28.9M Q2 '11: 28.1M Q3 '11: 28.1M Q1 '12: 28.2M Q2 '12: 28.2M Q3 '12: 28.2M Q1 '13: 28.3M Q2 '13: 28.4M Q3 '13: 31.3M Q1 '17: 44.4M Q2 '17: 44.7M Q3 '17: 44.9M Q1 '18: 48.2M Q2 '18: 53.9M Q3 '18: 54.7M Q1 '19: 52.8M Q2 '19: 54.6M Q3 '19: 54.5M Q1 '20: 54.9M Q2 '20: 55.1M Q3 '20: 55.2M Q1 '21: 56.5M Q2 '21: 56.9M Q3 '21: 57M Q1 '22: 56.1M Q2 '22: 56.8M Q3 '22: 57M Q1 '23: 57.4M Q2 '23: 57.5M Q3 '23: 57.6M Q1 '24: 57.8M Q2 '24: 58.2M Q3 '24: 58.3M Q1 '25: 58.5M Q2 '25: 59M Q3 '25: 59.1M Q1 '26: 59.5M Q2 '26: 60.2M Q3 '11 Q2 '13 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '16: -0.76 Q4 '16: -0.42 Q1 '17: -0.30 Q2 '17: -0.22 Q3 '17: -0.31 Q4 '17: -0.34 Q1 '18: -0.11 Q2 '18: 0.01 Q3 '18: 0.24 Q4 '18: 0.47 Q1 '19: 0.40 Q2 '19: 0.52 Q3 '19: 2.23 Q4 '19: 2.12 Q1 '20: 2.14 Q2 '20: 2.09 Q3 '20: 0.36 Q4 '20: 0.43 Q1 '21: 0.57 Q2 '21: 0.58 Q3 '21: 0.61 Q4 '21: 0.58 Q1 '22: 0.32 Q2 '22: 0.20 Q3 '22: 0.12 Q4 '22: 0.12 Q1 '23: 0.29 Q2 '23: 0.27 Q3 '23: 0.21 Q4 '23: 0.04 Q1 '24: -0.09 Q2 '24: -0.20 Q3 '24: -0.29 Q4 '24: -0.33 Q1 '25: -0.76 Q2 '25: -1.14 Q3 '25: -1.43 Q4 '25: -3.73 Q1 '26: -4.05 Q2 '26: -4.63 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.